Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
Dipak Panigrahy, Matthew L. Edin, Craig R. Lee, Sui Huang, Diane R. Bielenberg, Catherine E. Butterfield, Carmen M. Barnés, Akiko Mammoto, Tadanori Mammoto, Ayala Luria, Ofra Benny, Deviney M. Chaponis, Andrew C. Dudley, Emily R. Greene, Jo-Anne Vergilio, Giorgio Pietramaggiori, Sandra S. Scherer-Pietramaggiori, Sarah M. Short, Meetu Seth, Fred B. Lih, Kenneth B. Tomer, Jun Yang, Reto A. Schwendener, Bruce D. Hammock, John R. Falck, Vijaya L. Manthati, Donald E. Ingber, Arja Kaipainen, Patricia A. D’Amore, Mark W. Kieran, Darryl C. Zeldin
Dipak Panigrahy, Matthew L. Edin, Craig R. Lee, Sui Huang, Diane R. Bielenberg, Catherine E. Butterfield, Carmen M. Barnés, Akiko Mammoto, Tadanori Mammoto, Ayala Luria, Ofra Benny, Deviney M. Chaponis, Andrew C. Dudley, Emily R. Greene, Jo-Anne Vergilio, Giorgio Pietramaggiori, Sandra S. Scherer-Pietramaggiori, Sarah M. Short, Meetu Seth, Fred B. Lih, Kenneth B. Tomer, Jun Yang, Reto A. Schwendener, Bruce D. Hammock, John R. Falck, Vijaya L. Manthati, Donald E. Ingber, Arja Kaipainen, Patricia A. D’Amore, Mark W. Kieran, Darryl C. Zeldin
View: Text | PDF
Research Article

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice

  • Text
  • PDF
Abstract

Epoxyeicosatrienoic acids (EETs) are small molecules produced by cytochrome P450 epoxygenases. They are lipid mediators that act as autocrine or paracrine factors to regulate inflammation and vascular tone. As a result, drugs that raise EET levels are in clinical trials for the treatment of hypertension and many other diseases. However, despite their pleiotropic effects on cells, little is known about the role of these epoxyeicosanoids in cancer. Here, using genetic and pharmacological manipulation of endogenous EET levels, we demonstrate that EETs are critical for primary tumor growth and metastasis in a variety of mouse models of cancer. Remarkably, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in several tumor models. This systemic metastasis was not caused by excessive primary tumor growth but depended on endothelium-derived EETs at the site of metastasis. Administration of synthetic EETs recapitulated these results, while EET antagonists suppressed tumor growth and metastasis, demonstrating in vivo that pharmacological modulation of EETs can affect cancer growth. Furthermore, inhibitors of soluble epoxide hydrolase (sEH), the enzyme that metabolizes EETs, elevated endogenous EET levels and promoted primary tumor growth and metastasis. Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the critical importance of considering possible effects of EET-modulating drugs on cancer.

Authors

Dipak Panigrahy, Matthew L. Edin, Craig R. Lee, Sui Huang, Diane R. Bielenberg, Catherine E. Butterfield, Carmen M. Barnés, Akiko Mammoto, Tadanori Mammoto, Ayala Luria, Ofra Benny, Deviney M. Chaponis, Andrew C. Dudley, Emily R. Greene, Jo-Anne Vergilio, Giorgio Pietramaggiori, Sandra S. Scherer-Pietramaggiori, Sarah M. Short, Meetu Seth, Fred B. Lih, Kenneth B. Tomer, Jun Yang, Reto A. Schwendener, Bruce D. Hammock, John R. Falck, Vijaya L. Manthati, Donald E. Ingber, Arja Kaipainen, Patricia A. D’Amore, Mark W. Kieran, Darryl C. Zeldin

×

Figure 5

Pro-tumorigenic activity of EETs is mediated by VEGF production in the tumor stroma and loss of sEH.

Options: View larger image (or click on image) Download as PowerPoint
Pro-tumorigenic activity of EETs is mediated by VEGF production in the t...
(A) LLC tumors in VEGF-LacZ-Tr mice treated with 14,15-EET (15 μg/kg/d) show β-galactosidase staining (marker of VEGF production) in tumor endothelium and stromal fibroblasts (arrows). Scale bars: 20 μm. (B) Expression of sEH, but not CYP2J and CYP2C, is downregulated in tumor (TEC) versus normal (NEC) ECs (two left panels). Control tissue: mouse liver. Expression of sEH, but not CYP2J and CYP2C, is downregulated in tumor lysates from larger LLC tumors (>5 cm3) versus smaller LLC tumors (<1 cm3) (third panel). sEH expression (brown staining) is also downregulated in B16F10 melanoma liver metastasis compared with normal adjacent liver (far right panel). Scale bar: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts